---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011554"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:18:08.553540+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Fate Therapeutics shareholders approve 2022 Stock Plan, elect all director nominees

## Summary
- Stockholders approved 2022 Stock Option and Incentive Plan with 61.5M for, 23.2M against, 84.7K abstain.
- Class III directors Coughlin, Wolchko, and Agarwal elected; Agarwal received 69.7M for, 15.0M withheld.
- Ratification of Ernst & Young as auditor for FY2022 passed with 90.1M for, 69K against.
- Non-binding advisory vote on executive compensation passed with 75.4M for, 9.1M against.
- Broker non-votes of 5.5M shares on director election, say-on-pay, and plan approval.

## SEC filing metadata
- accession: 0000950170-22-011554
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017022011554/0000950170-22-011554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017022011554/fate-20220609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011554
- JSON: https://secwatch.observer/filing/0000950170-22-011554.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.